Our Roadmap


Q2 2019

Found­ing of Visotec GmbH
Visotec GmbH is found­ed by Helge Sud­kamp, Peter Koch, Moritz Molt­mann, and Michael Münst.


Q2 2020

Visotec now owns the entire IP to pro­tect its tech­nol­o­gy
We pos­sess all six patent fam­i­lies pro­tect­ing the technology.

Visotec suc­cess­ful­ly fin­ish­es first clin­i­cal tri­al
We suc­cess­ful­ly fin­ish the first clin­i­cal tri­al. We reach a sen­si­tiv­i­ty and speci­fici­ty of 0.94 and 0.95 in com­par­i­son to the gold stan­dard regard­ing the deci­sion of whether or not Anti-VEGF treat­ment is nec­es­sary. Please check our white paper for a full sum­ma­ry of the study results.


July 2020.

Visotec moves out of Uni­ver­si­ty


Q2 2021

Cur­rent engi­neer­ing unit, V6
Our newest engi­neer­ing unit con­tains our lat­est state-of-the-art tech­nol­o­gy and demon­strates its oper­a­tion prin­ci­ple.

We are here.

b3lineicon|b3icon-clipboard-chart||Clipboard Chart


Devel­op­ment of CE-marked, hand­held OCT device
We devel­op a CE-marked pilot prod­uct for the next gen­er­a­tion of clin­i­cal stud­ies. This pri­mar­i­ly includes the home care study, but also the devel­op­ment of treat­ment schemes with col­lab­o­rat­ing physicians.

Study: Acqui­si­tion of fol­low-up clin­i­cal data to reveal the full poten­tial of a home care OCT sys­tem
This study includes patients per­form­ing OCT scans on a dai­ly basis for the first time. The close mon­i­tor­ing enables us to visu­al­ize the pro­gres­sion of the dis­ease on a new level.

As AI algo­rithms require a wide ground truth we are also able to use the acquired data to sharp­en the pre­ci­sion of our AI algo­rithms. This helps to detect bio­mark­ers of age-relat­ed mac­u­lar degen­er­a­tion in an ear­ly stage to pro­vide care­free treatment.

b3lineicon|b3icon-shield-check||Shield Check


Study: OCT@Home demon­strat­ing inde­pen­dent oper­a­tion by the patient and improved sub­se­quent treat­ment
Based on the CE-marked hand­held device, this study involves patients using the device at home. The study shows that patients can use the device reli­ably and reg­u­lar­ly in their own homes. We are able to deter­mine the clin­i­cal val­ue from dai­ly fol­low-up OCT mea­sure­ments com­pared to stan­dard (month­ly) diagnostics.

b3lineicon|b3icon-group-round||Group Round


Devel­op­ment of scal­able con­sumer prod­uct
This step stream­lines the CE-marked device for effi­cient and scal­able pro­duc­tion.

Visotec is looking for investors. 

If you are inter­est­ed, we would be hap­py to hear from you.

9 + 8 =